May 10, 2021 -- Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose.
Sterilizing immunity is considered critical for blocking transmission of the virus, the company said. Data came from a preclinical mouse study that showed a single dose of AdCOVID blocked virus uptake in vaccinated mice compared to unvaccinated counterparts.
Altimmune plans to release phase I data from an AdCOVID clinical trial in June. The trial is evaluating three dose levels of the vaccine, according to the firm.